Clinical trials: Sweat Gland Diseases
Hidradenitis Suppurativa
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development.
- Trial name
- NCT06046729
- Testing
- Eltrekibart
- Where
- 74 sites in United States, Australia and 4 more
- Volunteers
- 352 people
- Sponsor
- Eli Lilly and Company
Hidradenitis Suppurativa
Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients
The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab.
- Trial name
- HOPE (NCT02739828)
- Testing
- Adalimumab
- Where
- 11 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa, Acne Inversa
Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are lacking.
- Trial name
- NCT04979520
- Testing
- Brodalumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Rockefeller University
Hidradenitis Suppurativa (HS)
Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease hidradenitis suppurativa (HS).
- Trial name
- Botox in HS (NCT07756346)
- Testing
- Botulinum Toxin A (Allergan, Inc, Irvine CA)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Massachusetts, Worcester
Hidradenitis Suppurativa
Anakinra in Hidradenitis Suppurativa
Aim of this double-blind, randomized, controlled clinical trial is to compare the safety and the efficacy of anakinra over placebo for the management of patients with hidradenitis suppurativa (HS) of Hurley II and Hurley III…
- Trial name
- NCT01558375
- Testing
- Water for injection, Anakinra
- Where
- 2 sites in Greece
- Volunteers
- 20 people
- Sponsor
- University of Athens
Hidradenitis Suppurativa
Aviclear for Hidradenitis Suppurativa (HS)
The objective is to evaluate the safety and efficacy of the Cutera 1726 nm laser system (also referred to as AviClear) for the treatment of HS.
- Trial name
- NCT06801795
- Testing
- AviClear
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Miami
Hidradenitis Suppurativa
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- NCT06921850
- Testing
- Bimekizumab
- Where
- 16 sites in United States, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.
- Trial name
- NCT06326476
- Testing
- Siplizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Alabama at Birmingham
Hyperhidrosis
Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis
The Purpose of the study is to evaluate the 1440nm Laser Assisted Selective Photothermolysis vs. Botulinum Toxin or miraDry® Microwave Thermolysis For Treatment of Axillary Hyperhidrosis.
- Trial name
- NCT01811004
- Testing
- miraDry, Nd:YAG Laser, Botox®
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cynosure, Inc.
Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa)
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Secukinumab is currently approved in Europe, US and China for the treatment of moderate to severe HS as a biologic agent targeting IL-17A.Two phase III clinical trials (SUNSHINE and SUNRISE) showed that 300 mg s.c.
- Conditions
- Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
- Trial name
- NCT07261072
- Testing
- Topical injection of Secukinmab, Subcutaneous injection of Secukinumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College
Hidradenitis Suppurativa
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
The purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa, and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab, after…
- Trial name
- NCT00134134
- Testing
- efalizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NYU Langone Health
Hyperhidrosis, Palmar Hyperhidrosis
Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group comparison study of AT-5214 in subjects with moderate to severe primary palmar hyperhidrosis (sweaty palms).
- Trial name
- NCT04263623
- Testing
- Dexmecamylamine HCl
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Atacama Therapeutics
Hyperhidrosis
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects.
- Trial name
- NCT02193139
- Testing
- WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- Watson Pharmaceuticals
Hidradenitis Suppurativa
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
The study is a randomized, proof of concept study. 30 patients aged 18 and over with HS will be included in this single center, randomized, double-blind, parallel-group study.
- Trial name
- NCT05997277
- Testing
- Deucravacitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Beth Israel Deaconess Medical Center
One Lung Ventilation OLV, Esophageal Atresia
The Effect of Dexmedetomidine on Oxygen During One Lung Ventilation in Pediatric Surgery.
The children who will undergo OLV (one lung ventilation) through general anesthesia will be divided into two groups: The first will be intravenous infusion of dexmedetomidine at 0.4 mcg / kg / hour, and the second will be…
- Conditions
- One Lung Ventilation OLV, Esophageal Atresia, Hydrocystoma, Pneumonectomy
- Trial name
- RCT (NCT04932746)
- Testing
- Dexmedetomidine
- Where
- Syria
- Volunteers
- 110 people
- Sponsor
- Damascus University
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Hidradenitis Suppurativa
To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12 in subjects with moderate to severe hidradenitis suppurativa.
- Trial name
- HIDRI2007 (NCT00827996)
- Testing
- adalimumab
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Hidradenitis Suppurativa
Treatment of Hidradenitis Suppurativa Using Etanercept
Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of HS.
- Trial name
- NCT00949546
- Testing
- etanercept
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Penn State University
Hyperhidrosis
Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
- Trial name
- NCT02100072
- Testing
- Nd:YAG 1440 nm laser
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cynosure, Inc.
Hidradenitis Suppurativa (HS)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
This study is a Phase Ic/II clinical trial conducted in Chinese patients with moderate-to-severe hidradenitis suppurativa (HS), aiming to evaluate the safety and efficacy of LT-002-158 tablets in the treatment of…
- Trial name
- NCT06932003
- Testing
- LT-002-158 Tablets
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.